**3.2 Ongoing trial for primary chemoablation**

An ongoing phase 2 study of UGN-102 for low-grade intermediate risk nonmuscle invasive bladder cancer [OPTIMA II] has enrolled 63 participants. They used 75 mg Mitomycin C [mitomycin C] in 56 mL admixture [1.33 mg mitomycin C per 1 mL of admixture], and six intravesical instillations were given weekly. The


#### **Table 1.**

*The internal devices used for hyperthermia.*

primary objective was the complete response rate three months after treatment. The trial completion date was December 2020, and results are awaited [22].
